New hope for tough myeloma: experimental drug SG2918 enters human trials
NCT ID NCT07454187
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called SG2918 in 40 people with relapsed or refractory multiple myeloma, a type of blood cancer that has returned or stopped responding to standard treatments. The main goal is to check the drug's safety and how well the body tolerates it, with early signs of effectiveness also being measured. Participants receive SG2918 by intravenous infusion every three weeks at different dose levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SG2918 (an experimental drug given by intravenous infusion every 3 weeks)
What this could lead to
If it works, this could point toward a new treatment option for patients with multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is an early-phase trial with only 40 participants, so results may not apply broadly. The drug may cause side effects or fail to control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
The First Affiliated Hospital Of Soochow University
Suzhou, Jiangsu, 215006, China
Contact Email: •••••@•••••
-
The Second Affiliated Hospital Of Xi an Jiaotong University (Xibei Hospital)
Xi’an, Shanxi, 710000, China
Contact Email: •••••@•••••
-
The Second Affiliated Hospital Zhejiang University School Of Medicine
Hangzhou, Zhejiang, 310056, China